View full meeting coverage »

Eyetube Meeting Coverage:

Retina Updates Spring 2020


Editorially Independent Content, Financially Supported by


Your 25-second video preview has ended.

to continue watching, please Log In or Register:

Log in / Register

Novel C5 Inhibitor for GA Growth

  Channels: Retina | Posted 5/13/2020

Karl Csaky, MD, PhD, reviews data from a clinical trial that evaluated the novel C5 inhibitor avacincaptad pegol (Zimura, IVERIC bio) for the treatment of patients with geographic atrophy. Dr. Csaky summarizes the study’s inclusion criteria, explains the study’s 12-month results, and previews future evaluations of this drug candidate.

Clinical Trials • geographic atrophy, GA • retina-meeting-recap

2 / 10 Series: Retina Updates Spring 2020

These programs are not affiliated with the official program of ARVO 2020.